Abstract: The present disclosure relates to a dose detection system for use in combination with a medication delivery device in which a dose setting member rotates relative to an actuator during dose delivery. The dose detection system includes a module which is removably attached to the medication delivery device. The module includes a dosing component attached to the actuator during dose delivery. The dosing component includes a light source and a light sensor. A sensed element is attached to the dose setting member and includes surface features detectable by the light sensor.

Abstract: A gripping attachment (10) is disclosed which facilitates the handling of a medication bottle (12). The medication bottle includes a container (14) having a cylindrical wall (16) extending parallel to a longitudinal axis. The container is closed at one end by a base wall (18) and has an opposed open end. The container receives a cap (20) on the open end to enclose the container. The gripping attachment comprises a sleeve portion (22) having a sleeve wall (24) defining an internal, cylindrical surface configured to removably attach to the container wall. The gripping attachment further comprises a leverage component connected to the sleeve portion to facilitate gripping the sleeve portion.

Abstract: The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Abstract: Automatic injection devices (i.e., auto-injectors) and methods are disclosed that use gas-generating chemical reactions for parenteral delivery of therapeutic fluids. The generated gas may place the auto-injector in a punctured configuration to puncture a patient's skin with a needle, an injected configuration to deliver the therapeutic fluid through the needle and into the puncture site, and/or a retracted configuration to withdraw the needle from the puncture site.

Abstract: The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.

Abstract: Pharmaceutical formulations for anti-CGRP antibodies, and methods of using the same, are provided which are useful as treatment for migraines, episodic headaches, chronic headaches, chronic cluster headaches, and episodic cluster headaches.

Abstract: Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.

Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.

Abstract: Medication delivery devices are provided having a dose delivery sensing capability. A sensed element is attached to a dose setting member of the device. The sensed element includes surface features radially-spaced from one another. A rotational sensor is attached to an actuator of the device. The rotational sensor includes a movable element that is contactable against the surface features. The rotational sensor is configured to generate a signal in response to the movement of the movable element over the surface features during their rotation. A controller is operatively coupled to the rotational sensor, and in response to receiving the generated signal, the controller is configured to determine a number of the surface features passing the movable element of the rotational sensor during dose delivery. The number can be associated with an amount of dose delivered. Sensing can be provided in a module or integrated in device.

Abstract: The present invention relates to a combination of anti-human VEGFR-2 antibodies and human EGFR tyrosine kinase inhibitors for the treatment of T790M-positive EGFR-mutant non-small cell lung cancer.

Abstract: Medication delivery devices, sensing systems, and methods are disclosed for determining the relative axial and rotational movements of its members to determine the amount of a dose set and/or delivered by the medication delivery device. A sensing system comprises a barrel sensor system (100), a drive sleeve sensor system (130), and/or an axial sensor system (140). The barrel sensor system (100) is for detecting the absolute relative angular position of the barrel relative to the housing during dose setting. The drive sleeve sensor system (130) is for detecting the absolute relative angular position of the drive sleeve relative to the housing during dose delivery. The axial sensor system (140) is for detecting the relative axial positions of the dose dial relative to the housing during dose setting and delivery. A controller receives outputs from the sensor systems corresponding to the absolute relative positions to determine the actual amounts of dose set and delivered.

Abstract: The present invention relates to novel variants of human BMP7 protein. The invention embodies vectors and host cells for the propagation of nucleic acid sequences encoding said proteins and the production thereof. Also disclosed are methods for the treatment of cancer, cartilage damage and degeneration, pain associated with osteoarthritis, or bone healing.

Abstract: The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor.

Abstract: A medication delivery device with a sensing system to determine at least one of a dose set and a dose delivery. The sensing system is operable to detect relative rotational positions of first and second members of the device which are indicative of at least one of an amount of a dose set and an amount of a dose delivered by operation of the device, and generate outputs correlated to such relative rotational positions. The system includes a wiper coupled to the first member, and a sensing band coupled to the second member for physically contacting the wiper as the second member rotates relative to the first member. A controller electrically communicates with the sensing system to determine, based on the generated outputs of the sensing system, at least one of the amount of the dose set and the amount of the dose delivered by operation of the device.

Abstract: A device for removing a protective shield such as a needle shield is disclosed. The device includes a cup shaped body with a sidewall, a distal bottom wall and a proximal opening. The protective shield is insertable into the cup shaped body through its proximal opening. Fingers are disposed opposite each other in openings in the sidewall. The fingers are flexibly coupled with the sidewall at a proximal end of the finger and can be resiliently biased inwardly to engage the protective shield. Each finger includes at least one projection for engaging the protective shield. The fingers may also include a distal engagement surface for engaging a lip on the protective shield.

Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.